In a report released today, Matt Hewitt from Craig-Hallum maintained a Buy rating on Maravai Lifesciences Holdings (MRVI – Research Report).

TriLink BioTechnologies (TriLink®), a Maravai® LifeSciences company (NASDAQ: MRVI) and global provider of life science ...

Justin Barbosa, GM and Vice President of TriLink Discovery, added “By integrating Molecular Assemblies technology into ...

TriLink BioTechnologies, a Maravai LifeSciences company (MRVI), has partnered with, Avantor (AVTR) to expand availability of its innovative ...

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI – Get Free Report) was the target of some unusual options trading on ...

Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics and novel vaccines and to support research on human diseases.

Maravai Lifesciences Holdings Inc (MRVI) stock saw a decline, ending the day at $5.5 which represents a decrease of $-0.11 or -1.96% from the prior close of $5.61. The stock opened at $5.79 and ...

TriLink BioTechnologies, a Maravai LifeSciences company and provider of life science reagents and services, has partnered ...

Their team has made great strides in designing and developing an enzymatic DNA synthesis platform with exciting technical advantages over traditional chemical synthesis," said Trey Martin, CEO of ...

CEO of Maravai LifeSciences. “We plan to further evolve and enhance Molecular Assemblies’ workflows to push the limits of oligo length and purity, and to lower costs by vertically integrating ...